Asia-Pacific’s largest specialist biotech CRO Novotech has been selected for the Komipharm International clin...
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for bio...
US based AVROBIO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic...
PPD, Inc. ( PPD ) has expanded its China operations and leadership team to provide more international and Chin...
Genome & Company, a clinical-stage biotechnology company based in Seongnam, Republic of Korea, has announced th...
Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrou...
CStone Pharmaceuticals has announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Co...
French firm Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of canc...
Eisai Co., Ltd. presented its latest information on its in-house discovered and developed eribulin mesylate (halich...
Gracell Biotechnologies Co. Ltd., a clinical-stage immune cell therapy company, has announced it will present at leading...
Liver cancer is the fourth most common cancer among men and affects approximately 24 individuals in every 100,000 people...
NeuClone Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality ...
Japan based Takeda Pharmaceutical Company Limited announced the presentation of the results of tourmaline-AL1 trial in a...
CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therap...
Seattle Genetics, Inc. and Astellas Pharma Inc.have announced a clinical collaboration agreement with Merck, k...
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves over...
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epi...
CStone Pharmaceuticals on 20 Nov 2019 announced that the first patient has been dosed in Phase I bridging the registrati...
